52.84

0.95% 0.5199

Biomarin Pharmaceutical Inc (BMRN)

Overview News Price History Option Chain Financials Discussions Forecast

Biomarin Pharmaceutical Inc stock is traded at $52.84, with a volume of 711.73K. It is up +0.95% in the last 24 hours and down -2.35% over the past month. BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Previous Close:

$52.32

Open:

$52.585

24h Volume:

711.73K

Relative Volume:

0.34

Market Cap:

$10.14B

Revenue:

$2.95B

Net Income/Loss:

$523.88M

P/E Ratio:

19.64

EPS:

2.69

Net Cash Flow:

$620.18M

1W Performance:

-5.02%

1M Performance:

-2.35%

6M Performance:

-7.04%

1Y Performance:

-24.92%

1-Day Range:

$51.85

$52.87

1-Week Range:

$51.78

$56.26

52-Week Range:

$51.78

$73.51

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name

Biomarin Pharmaceutical Inc

Sector

Healthcare (1145)

Industry

Biotechnology (637)

Phone

(415) 506-6700

Address

105 DIGITAL DRIVE, NOVATO, CA

Employee

3,040

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

BMRN's Discussions on Twitter

Compare BMRN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMRN Biomarin Pharmaceutical Inc	52.83	10.05B	2.95B	523.88M	620.18M	2.69
VRTX Vertex Pharmaceuticals Inc	408.30	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	470.96	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	556.06	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	807.20	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	331.64	35.16B	4.56B	-176.77M	225.30M	-1.7177

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-08-25	Initiated	H.C. Wainwright	Neutral
Sep-03-25	Initiated	Raymond James	Outperform
Jul-03-25	Resumed	Morgan Stanley	Overweight
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-24	Initiated	Evercore ISI	Outperform
Nov-15-23	Initiated	Wells Fargo	Overweight
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Bernstein	Underperform
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral
Jan-30-23	Initiated	BMO Capital Markets	Market Perform
Jan-18-23	Initiated	Canaccord Genuity	Hold
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight
Jun-13-22	Resumed	Wedbush	Neutral
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Oct-07-21	Resumed	Jefferies	Buy
Sep-09-21	Upgrade	Stifel	Hold → Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-04-21	Resumed	Guggenheim	Buy
Mar-01-21	Upgrade	Evercore ISI	In-line → Outperform
Aug-20-20	Downgrade	Citigroup	Buy → Neutral
Aug-20-20	Downgrade	William Blair	Outperform → Mkt Perform
Aug-19-20	Downgrade	Evercore ISI	Outperform → In-line
Aug-19-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-19-20	Downgrade	Stifel	Buy → Hold
Jul-08-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-06-20	Reiterated	Citigroup	Buy
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Jan-24-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-27-19	Upgrade	Barclays	Equal Weight → Overweight
Nov-12-19	Initiated	SunTrust	Buy
Oct-17-19	Resumed	BofA/Merrill	Buy
May-23-19	Resumed	Citigroup	Buy
Apr-09-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-14-18	Initiated	Wolfe Research	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-07-18	Reiterated	Stifel	Buy
Aug-03-18	Reiterated	Stifel	Buy

View All

Biomarin Pharmaceutical Inc Stock (BMRN) Latest News

08:38 AM

What data driven models say about BioMarin Pharmaceutical Inc.’s futureStock Surge & Risk Managed Investment Strategies - newser.com

08:38 AM

08:07 AM

Understanding BioMarin Pharmaceutical Inc.’s price movementQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com

08:07 AM

07:57 AM

BioMarin Pharmaceutical Inc. stock outlook for YEARRisk Management & Daily Growth Stock Tips - newser.com

07:57 AM

05:44 AM

Real time social sentiment graph for BioMarin Pharmaceutical Inc.2025 Fundamental Recap & AI Driven Stock Reports - newser.com

05:44 AM

01:54 AM

Price momentum metrics for BioMarin Pharmaceutical Inc. explainedJuly 2025 Opening Moves & AI Based Buy/Sell Signal Reports - newser.com

01:54 AM

01:02 AM

Ascendis Pharma Develops Sustained-Release Therapy to Compete with BioMarin’s Voxzogo for Achondroplasia Treatment - geneonline.com

01:02 AM

12:03 PM

Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace

12:03 PM

Oct 12, 2025

What MACD signals say about BioMarin Pharmaceutical Inc.Profit Target & Fast Exit/Entry Strategy Plans - newser.com

Oct 12, 2025

Can BioMarin Pharmaceutical Inc. stock reach $100 price targetQuarterly Market Summary & Weekly Chart Analysis and Trade Guides - newser.com

Oct 12, 2025

Board of the Pension Protection Fund Invests $445,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Oct 12, 2025

Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Oct 12, 2025

Oct 11, 2025

BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo

Oct 11, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 12-Month LowTime to Sell? - MarketBeat

Oct 11, 2025

Leerink Partnrs Has Negative Outlook of BMRN Q1 Earnings - MarketBeat

Oct 11, 2025

Callan Family Office LLC Purchases 47,264 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Oct 11, 2025

Oct 10, 2025

10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - TradingView

Oct 10, 2025

Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD By Investing.com - Investing.com South Africa

Oct 10, 2025

Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD - Investing.com India

Oct 10, 2025

Relative strength of BioMarin Pharmaceutical Inc. in sector analysisQuarterly Investment Review & Community Trade Idea Sharing - newser.com

Oct 10, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $119.00 - MarketBeat

Oct 10, 2025

Oct 09, 2025

BioMarin Pharmaceutical's (BMRN) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025

Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire

Oct 09, 2025

Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance

Oct 09, 2025

Oct 08, 2025

Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? - MSN

Oct 08, 2025

Oct 07, 2025

Biomarin Pharmaceutical expects Q3 will include acquired IPR&D charges of about $221 million - MarketScreener

Oct 07, 2025

BioMarin projects $221 million IPR&D charge from Inozyme acquisition - Investing.com

Oct 07, 2025

AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.

Oct 07, 2025

14 Biotech Stocks with High Potential - Insider Monkey

Oct 07, 2025

Oct 06, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - sharewise.com

Oct 06, 2025

Oct 05, 2025

Real time alert setup for BioMarin Pharmaceutical Inc. performanceIPO Watch & Reliable Intraday Trade Plans - newser.com

Oct 05, 2025

How BioMarin Pharmaceutical Inc. stock performs in stagflationM&A Rumor & Long-Term Safe Investment Ideas - newser.com

Oct 05, 2025

Oct 04, 2025

Should Positive Phase 3 PALYNZIQ Results Prompt Action From BioMarin (BMRN) Investors? - Sahm

Oct 04, 2025

Robeco Institutional Asset Management B.V. Increases Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Oct 04, 2025

Oct 03, 2025

BioMarin Pharmaceutical Inc.’s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials - MSN

Oct 03, 2025

Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story? - Yahoo Finance

Oct 03, 2025

J. Safra Sarasin Holding AG Boosts Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Oct 03, 2025

Is BioMarin Pharmaceutical Inc. stock a safe buy before earningsMarket Weekly Review & Momentum Based Trading Ideas - newser.com

Oct 03, 2025

BioMarin Pharmaceutical (BMRN): Evaluating Valuation as PALYNZIQ Clinical Success Contrasts With 52-Week Share Price Low - Sahm

Oct 03, 2025

How institutional ownership impacts BioMarin Pharmaceutical Inc. stockPortfolio Return Report & Free Accurate Trade Setup Notifications - newser.com

Oct 03, 2025

Oct 02, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Oct 02, 2025

Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors - Insider Monkey

Oct 02, 2025

Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline - Yahoo Finance

Oct 02, 2025

New Wave Wealth Advisors LLC Raises Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Oct 02, 2025

Oct 01, 2025